Skip to main content
European Commission logo print header

Development of a first-in-class inhibitor of FIH for cancer immunotherapy

Obiettivo

We plan to carry out a valorisation project for a series of novel small molecule inhibitors of Factor Inhibiting HIF (FIH) that we have developed for the treatment of lung cancer, as a next-generation therapeutic approach in the field of immuno-oncology.
The valorisation plan will include: clarification of IP rights and strategy, establishing contacts with potential investors and pharma partners, and verification of the potential of start-up creation. Moreover, valorisation activities will include progression of hits against FIH into a lead optimisation campaign with the aim of designating a candidate drug.

Meccanismo di finanziamento

HORIZON-AG-LS - HORIZON Lump Sum Grant

Istituzione ospitante

ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS
Contribution nette de l'UE
€ 150 000,00
Indirizzo
PARQUE TECNOLOGICO EDIFICIO 801 A
48160 Derio Vizcaya
Spagna

Mostra sulla mappa

Regione
Noreste País Vasco Bizkaia
Tipo di attività
Research Organisations
Collegamenti
Costo totale
Nessun dato

Beneficiari (1)